News
Cancer Genome Project will put San Antonio in research spotlight
South Texas Accelerated Research Therapeutics' Dr. Anthony Tolcher says the Alamo City has an opportunity ...
San Antonio urology professors lead nation in research funding
By James Aldridge, San Antonio Business Journal University of Texas Health Science Center at San Antonio ...
Events
3rd Annual Medical Tourism Research Conference
February 13-15, 2012 Locaton: Omni La Mansion del Rio, 112 College Street, San Antonio, Texas 78205 Featuring: ...Industry Publications
The Mission
The Mission is published by the University of Texas Health Science Center.
UTSA Discovery
UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...
San Antonio Business Journal
The U.S. Patent and Trademark Office issued a new patent to GenSpera Inc. to cover the intellectual property on the company’s second anti-cancer drug compound currently in development.
The patent 7,635,682 covers GenSpera’s drug G-115 — which is activated in prostate tumors by an enzyme. In preclinical testing, G-115 was shown to inhibit the growth of tumors in animal models of prostate cancer. Obtaining the patent rights to this drug is key as GenSpera seeks formal Food and Drug Administration approval.
GenSpera’s President and CEO Craig Dionne says that the term of the patent will extend into 2026. This will give the company time to enter into discussions with future development partners.
San Antonio-based GenSpera is a development stage oncology company with a technology platform that delivers drugs directly into tumors.
